A Randomized, Open-label, Non-inferiority Designed Phase IIIb Clinical Trial to Evaluate the Immunogenicity and Safety of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) Between 2 Doses in Adolescent Females Aged 9-14 Years/3 Doses in Adolescent Females Aged 9-17 Years and Age/Immunization Schedule Bridging in Females Aged 18-26 Year
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Quadrivalent-human-papillomavir0us-vaccine (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- 15 Oct 2024 New trial record